Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

Cytokine

Volumn 101, Issue , 2018, Pages 56-63

  Mitoma, Hiroki ^a   Horiuchi, Takahiko ^b   Tsukamoto, Hiroshi ^c   Ueda, Naoyasu ^d  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^c Shin Kokura Hospital   (Japan)

^d MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

Author keywords

Anti TNF therapy; Inflammatory bowel disease; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LYMPHOTOXIN; LYMPHOTOXIN ALPHA BETA; LYMPHOTOXIN ALPHA2BETA1; LYMPHOTOXIN ALPHA3; LYMPHOTOXIN BETA RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MACROGOL; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; COMPLEMENT DEPENDENT CYTOTOXICITY; CROHN DISEASE; CYTOKINE RESPONSE; DEXTRAN SULFATE SODIUM-INDUCED COLITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; IN VIVO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIASIS; REMISSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; MOUSE;

ADALIMUMAB; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CERTOLIZUMAB PEGOL; DISEASE MODELS, ANIMAL; ETANERCEPT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MICE; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84994085512     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.08.014     Document Type: Article

References (103)

1. Tracey, D., Klareskog, L., Sasso, E.H., Salfeld, J.G., Tak, P.P., Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117:2 (2008), 244–279.
2. Bradley, J.R., TNF-mediated inflammatory disease. J. Pathol. 214:2 (2008), 149–160.
3. Perez, C., Albert, I., DeFay, K., Zachariades, N., Gooding, L., Kriegler, M., A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:2 (1990), 251–258.
4. Horiuchi, T., Mitoma, H., Harashima, S., Tsukamoto, H., Shimoda, T., Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford, England) 49:7 (2010), 1215–1228.
5. Alexopoulou, L., Pasparakis, M., Kollias, G., A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur. J. Immunol. 27:10 (1997), 2588–2592.
6. Georgopoulos, S., Plows, D., Kollias, G., Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 46:2 (1996), 86–97.
7. Eissner, G., Kolch, W., Scheurich, P., Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 15:5 (2004), 353–366.
8. Eissner, G., Kirchner, S., Lindner, H., Kolch, W., Janosch, P., Grell, M., Scheurich, P., Andreesen, R., Holler, E., Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J. Immunol. (Baltimore, Md.: 1950) 164:12 (2000), 6193–6198.
9. Harashima, S., Horiuchi, T., Hatta, N., Morita, C., Higuchi, M., Sawabe, T., Tsukamoto, H., Tahira, T., Hayashi, K., Fujita, S., Niho, Y., Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J. Immunol. (Baltimore, Md.: 1950) 166:1 (2001), 130–136.
10. Rossol, M., Meusch, U., Pierer, M., Kaltenhauser, S., Hantzschel, H., Hauschildt, S., Wagner, U., Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J. Immunol. (Baltimore, Md.: 1950) 179:6 (2007), 4239–4248.
11. Vudattu, N.K., Holler, E., Ewing, P., Schulz, U., Haffner, S., Burger, V., Kirchner, S., Andreesen, R., Eissner, G., Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells. Immunology 115:4 (2005), 536–543.
12. Xin, L., Wang, J., Zhang, H., Shi, W., Yu, M., Li, Q., Jiang, X., Gong, F., Gardner, K., Li, Q.Q., Li, Z., Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated 'reverse signaling’. Int. J. Mol. Med. 18:5 (2006), 885–892.
13. Yu, M., Shi, W., Zhang, J., Niu, L., Chen, Q., Yan, D., Liu, T., Jing, W., Jiang, X., Wei, F., Yin, B., Zhang, W., Li, Q., Li, Z., Influence of reverse signaling via membrane TNF-alpha on cytotoxicity of NK92 cells. Eur. J. Cell Biol. 88:3 (2009), 181–191.
14. Blandizzi, C., Gionchetti, P., Armuzzi, A., Caporali, R., Chimenti, S., Cimaz, R., Cimino, L., Lapadula, G., Lionetti, P., Marchesoni, A., Marcellusi, A., Mennini, F.S., Salvarani, C., Girolomoni, G., The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int. J. Immunopathol. Pharmacol. 27:1 Suppl (2014), 1–10.
15. Arida, A., Fragiadaki, K., Giavri, E., Sfikakis, P.P., Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin. Arthritis Rheum. 41:1 (2011), 61–70.
16. Sedger, L.M., McDermott, M.F., TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev. 25:4 (2014), 453–472.
17. Levin, A.D., Wildenberg, M.E., van den Brink, G.R., Mechanism of action of Anti-TNF therapy in inflammatory bowel disease. J. Crohn's Colitis 10:8 (2016), 989–997.
18. Da, W., Zhu, J., Wang, L., Lu, Y., Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis. Adv. Therapy 30:5 (2013), 541–553.
19. Sandborn, W.J., Feagan, B.G., Stoinov, S., Honiball, P.J., Rutgeerts, P., Mason, D., Bloomfield, R., Schreiber, S., Certolizumab pegol for the treatment of Crohn's disease. New Engl. J. Med. 357:3 (2007), 228–238.
20. Sandborn, W.J., Schreiber, S., Feagan, B.G., Rutgeerts, P., Younes, Z.H., Bloomfield, R., Coteur, G., Guzman, J.P., D'Haens, G.R., Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin. Gastroenterol. Hepatol.: Official Clin. Practice J. Am. Gastroenterol. Assoc. 9:8 (2011), 670–678.e3.
21. Rutgeerts, P., Sandborn, W.J., Fedorak, R.N., Rachmilewitz, D., Tarabar, D., Gibson, P., Haagen Nielsen, O., Wild, G., Schreiber, S., Pena Rossi, C., Zignani, M., Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol.: Official Clin. Practice J. Am. Gastroenterol. Assoc. 4:7 (2006), 888–893.
22. Wallis, R.S., Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet. Infect. Dis 8:10 (2008), 601–611.
23. Wallis, R.S., Ehlers, S., Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin. Arthritis Rheum. 34:5 Suppl1 (2005), 34–38.
24. Derer, S., Till, A., Haesler, R., Sina, C., Grabe, N., Jung, S., Nikolaus, S., Kuehbacher, T., Groetzinger, J., Rose-John, S., Rosenstiel, P.C., Schreiber, S., MTNF reverse signalling induced by TNFalpha antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease. Gut 62:3 (2013), 376–386.
25. Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D.K., Salfeld, J., Sasso, E.H., Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin. Immunol. (Orlando, Fla.) 131:2 (2009), 308–316.
26. Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., Harada, M., Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128:2 (2005), 376–392.
27. Mitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., Harada, M., Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 58:5 (2008), 1248–1257.
28. Nesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., Bourne, T., Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis. 13:11 (2007), 1323–1332.
29. Ringheanu, M., Daum, F., Markowitz, J., Levine, J., Katz, S., Lin, X., Silver, J., Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm. Bowel Dis. 10:6 (2004), 801–810.
30. Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.Y., Shealy, D., Wagner, C., Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301:2 (2002), 418–426.
31. Shealy, D.J., Cai, A., Staquet, K., Baker, A., Lacy, E.R., Johns, L., Vafa, O., Gunn, G. 3rd, Tam, S., Sague, S., Wang, D., Brigham-Burke, M., Dalmonte, P., Emmell, E., Pikounis, B., Bugelski, P.J., Zhou, H., Scallon, B.J., Giles-Komar, J., Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. mAbs 2:4 (2010), 428–439.
32. Ueda, N., Tsukamoto, H., Mitoma, H., Ayano, M., Tanaka, A., Ohta, S., Inoue, Y., Arinobu, Y., Niiro, H., Akashi, K., Horiuchi, T., The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm. Bowel Dis. 19:6 (2013), 1224–1231.
33. Van den Brande, J.M., Braat, H., van den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I., van Montfrans, C., Hommes, D.W., Peppelenbosch, M.P., van Deventer, S.J., Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:7 (2003), 1774–1785.
34. Vos, A.C., Wildenberg, M.E., Duijvestein, M., Verhaar, A.P., van den Brink, G.R., Hommes, D.W., Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 140:1 (2011), 221–230.
35. Wojtal, K.A., Rogler, G., Scharl, M., Biedermann, L., Frei, P., Fried, M., Weber, A., Eloranta, J.J., Kullak-Ublick, G.A., Vavricka, S.R., Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS ONE, 7(8), 2012, e43361.
36. Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., Yamaguchi, T., Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. (Baltimore, Md.: 1950) 184:4 (2010), 1968–1976.
37. Biancheri, P., Brezski, R.J., Di Sabatino, A., Greenplate, A.R., Soring, K.L., Corazza, G.R., Kok, K.B., Rovedatti, L., Vossenkamper, A., Ahmad, N., Snoek, S.A., Vermeire, S., Rutgeerts, P., Jordan, R.E., MacDonald, T.T., Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 149:6 (2015), 1564–1574.e3.
38. Palframan, R., Airey, M., Moore, A., Vugler, A., Nesbitt, A., Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J. Immunol. Methods 348:1–2 (2009), 36–41.
39. Agostini, C., Sancetta, R., Cerutti, A., Semenzato, G., Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. J. Leukoc. Biol. 58:5 (1995), 495–500.
40. Armstrong, L., Thickett, D.R., Christie, S.J., Kendall, H., Millar, A.B., Increased expression of functionally active membrane-associated tumor necrosis factor in acute respiratory distress syndrome. Am. J. Respir. Cell Mol. Biol. 22:1 (2000), 68–74.
41. Caron, G., Delneste, Y., Aubry, J.P., Magistrelli, G., Herbault, N., Blaecke, A., Meager, A., Bonnefoy, J.Y., Jeannin, P., Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. Eur. J. Immunol. 29:11 (1999), 3588–3595.
42. Fishman, M., Cytolytic activities of activated macrophages versus paraformaldehyde-fixed macrophages; soluble versus membrane-associated TNF. Cell. Immunol. 137:1 (1991), 164–174.
43. Horiuchi, T., Morita, C., Tsukamoto, H., Mitoma, H., Sawabe, T., Harashima, S., Kashiwagi, Y., Okamura, S., Increased expression of membrane TNF-alpha on activated peripheral CD8+ T cells in systemic lupus erythematosus. Int. J. Mol. Med. 17:5 (2006), 875–879.
44. Kresse, M., Latta, M., Kunstle, G., Riehle, H.M., van Rooijen, N., Hentze, H., Tiegs, G., Biburger, M., Lucas, R., Wendel, A., Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. J. Immunol. (Baltimore, Md.: 1950) 175:6 (2005), 4076–4083.
45. Peck, R., Brockhaus, M., Frey, J.R., Cell surface tumor necrosis factor (TNF) accounts for monocyte- and lymphocyte-mediated killing of TNF-resistant target cells. Cell. Immunol. 122:1 (1989), 1–10.
46. Birkland, T.P., Sypek, J.P., Wyler, D.J., Soluble TNF and membrane TNF expressed on CD4+ T lymphocytes differ in their ability to activate macrophage antileishmanial defense. J. Leukoc. Biol. 51:3 (1992), 296–299.
47. Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K.A., Gerhart, M., Davis, R., Fitzner, J.N., Johnson, R.S., Paxton, R.J., March, C.J., Cerretti, D.P., A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:6618 (1997), 729–733.
48. Lazdins, J.K., Grell, M., Walker, M.R., Woods-Cook, K., Scheurich, P., Pfizenmaier, K., Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. J. Exp. Med. 185:1 (1997), 81–90.
49. Tang, P., Hung, M.C., Klostergaard, J., Human pro-tumor necrosis factor is a homotrimer. Biochemistry 35:25 (1996), 8216–8225.
50. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., Scheurich, P., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:5 (1995), 793–802.
51. Domonkos, A., Udvardy, A., Laszlo, L., Nagy, T., Duda, E., Receptor-like properties of the 26 kDa transmembrane form of TNF. Eur. Cytokine Netw. 12:3 (2001), 411–419.
52. Fluhrer, R., Grammer, G., Israel, L., Condron, M.M., Haffner, C., Friedmann, E., Bohland, C., Imhof, A., Martoglio, B., Teplow, D.B., Haass, C., A gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD aspartyl protease SPPL2b. Nat. Cell Biol. 8:8 (2006), 894–896.
53. Friedmann, E., Hauben, E., Maylandt, K., Schleeger, S., Vreugde, S., Lichtenthaler, S.F., Kuhn, P.H., Stauffer, D., Rovelli, G., Martoglio, B., SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat. Cell Biol. 8:8 (2006), 843–848.
54. Vandenabeele, P., Declercq, W., Beyaert, R., Fiers, W., Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5:10 (1995), 392–399.
55. Chan, F.K., Chun, H.J., Zheng, L., Siegel, R.M., Bui, K.L., Lenardo, M.J., A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science (New York, N.Y.) 288:5475 (2000), 2351–2354.
56. MacEwan, D.J., TNF ligands and receptors–a matter of life and death. Br. J. Pharmacol. 135:4 (2002), 855–875.
57. Carpentier, I., Coornaert, B., Beyaert, R., Function and regulation of tumor necrosis factor receptor type 2. Curr. Med. Chem. 11:16 (2004), 2205–2212.
58. Higuchi, M., Nagasawa, K., Horiuchi, T., Oike, M., Ito, Y., Yasukawa, M., Niho, Y., Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation–characterization of membrane TNF-alpha. Clin. Immunol. Immunopathol. 82:2 (1997), 133–140.
59. Watts, A.D., Hunt, N.H., Wanigasekara, Y., Bloomfield, G., Wallach, D., Roufogalis, B.D., Chaudhri, G., A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling’. EMBO J. 18:8 (1999), 2119–2126.
60. Kohno, T., Tam, L.T., Stevens, S.R., Louie, J.S., Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J. Investig. Dermatol. Symp. Proc./The Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research 12:1 (2007), 5–8.
61. Arora, T., Padaki, R., Liu, L., Hamburger, A.E., Ellison, A.R., Stevens, S.R., Louie, J.S., Kohno, T., Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45:2 (2009), 124–131.
62. Mitoma, H., Horiuchi, T., Tsukamoto, H., Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 126:3 (2004), 934–935 author reply 935-6.
63. Ruddle, N.H., Lymphotoxin and TNF: how it all began-a tribute to the travelers. Cytokine Growth Factor Rev. 25:2 (2014), 83–89.
64. Calmon-Hamaty, F., Combe, B., Hahne, M., Morel, J., Lymphotoxin alpha stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 53:2 (2011), 207–214.
65. Buhrmann, C., Shayan, P., Aggarwal, B.B., Shakibaei, M., Evidence that TNF-beta (lymphotoxin alpha) can activate the inflammatory environment in human chondrocytes. Arthritis Res. Ther., 15(6), 2013, R202.
66. Neregard, P., Krishnamurthy, A., Revu, S., Engstrom, M., af Klint, E., Catrina, A.I., Etanercept decreases synovial expression of tumour necrosis factor-alpha and lymphotoxin-alpha in rheumatoid arthritis. Scand. J. Rheumatol. 43:2 (2014), 85–90.
67. Kennedy, W.P., Simon, J.A., Offutt, C., Horn, P., Herman, A., Townsend, M.J., Tang, M.T., Grogan, J.L., Hsieh, F., Davis, J.C., Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res. Ther., 16(5), 2014, 467.
68. Spahn, T.W., Muller, M.K., Domschke, W., Kucharzik, T., Role of lymphotoxins in the development of Peyer's patches and mesenteric lymph nodes: relevance to intestinal inflammation and treatment. Ann. N. Y. Acad. Sci. 1072 (2006), 187–193.
69. Shohet, J.M., Bergamaschini, L., Davis, A.E., Carroll, M.C., Localization of the human complement component C3 binding site on the IgG heavy chain. J. Biol. Chem. 266:28 (1991), 18520–18524.
70. Shohet, J.M., Pemberton, P., Carroll, M.C., Identification of a major binding site for complement C3 on the IgG1 heavy chain. J. Biol. Chem. 268:8 (1993), 5866–5871.
71. Vidarte, L., Pastor, C., Mas, S., Blazquez, A.B., de los Rios, V., Guerrero, R., Vivanco, F., Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1. J. Biol. Chem. 276:41 (2001), 38217–38223.
72. Vivanco, F., Munoz, E., Vidarte, L., Pastor, C., The covalent interaction of C3 with IgG immune complexes. Mol. Immunol. 36:13–14 (1999), 843–852.
73. Sahu, A., Pangburn, M.K., Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation. J. Biol. Chem. 269:46 (1994), 28997–29002.
74. Siberil, S., Dutertre, C.A., Boix, C., Bonnin, E., Menez, R., Stura, E., Jorieux, S., Fridman, W.H., Teillaud, J.L., Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol. Lett. 106:2 (2006), 111–118.
75. ten Hove, T., van Montfrans, C., Peppelenbosch, M.P., van Deventer, S.J., Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50:2 (2002), 206–211.
76. Van den Brande, J.M., Koehler, T.C., Zelinkova, Z., Bennink, R.J., te Velde, A.A., ten Cate, F.J., van Deventer, S.J., Peppelenbosch, M.P., Hommes, D.W., Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56:4 (2007), 509–517.
77. Bedini, C., Nasorri, F., Girolomoni, G., Pita, O., Cavani, A., Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br. J. Dermatol. 157:2 (2007), 249–258.
78. Caprioli, F., Bose, F., Rossi, R.L., Petti, L., Vigano, C., Ciafardini, C., Raeli, L., Basilisco, G., Ferrero, S., Pagani, M., Conte, D., Altomare, G., Monteleone, G., Abrignani, S., Reali, E., Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. Inflamm. Bowel Dis. 19:4 (2013), 729–739.
79. Wallis, R.S., Broder, M.S., Wong, J.Y., Hanson, M.E., Beenhouwer, D.O., Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis.: Official Publ. Infect. Dis. Soc. Am. 38:9 (2004), 1261–1265.
80. Bruns, H., Meinken, C., Schauenberg, P., Harter, G., Kern, P., Modlin, R.L., Antoni, C., Stenger, S., Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Investig. 119:5 (2009), 1167–1177.
81. Atreya, R., Zimmer, M., Bartsch, B., Waldner, M.J., Atreya, I., Neumann, H., Hildner, K., Hoffman, A., Kiesslich, R., Rink, A.D., Rau, T.T., Rose-John, S., Kessler, H., Schmidt, J., Neurath, M.F., Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. Gastroenterology 141:6 (2011), 2026–2038.
82. Kleijwegt, F.S., Laban, S., Duinkerken, G., Joosten, A.M., Zaldumbide, A., Nikolic, T., Roep, B.O., Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J. Immunol. (Baltimore, Md.: 1950) 185:3 (2010), 1412–1418.
83. Nagar, M., Jacob-Hirsch, J., Vernitsky, H., Berkun, Y., Ben-Horin, S., Amariglio, N., Bank, I., Kloog, Y., Rechavi, G., Goldstein, I., TNF activates a NF-κB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J. Immunol. (Baltimore, Md.: 1950) 184:7 (2010), 3570–3581.
84. Boschetti, G., Nancey, S., Sardi, F., Roblin, X., Flourie, B., Kaiserlian, D., Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm. Bowel Dis. 17:1 (2011), 160–170.
85. Toubi, E., Kessel, A., Mahmudov, Z., Hallas, K., Rozenbaum, M., Rosner, I., Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann. N. Y. Acad. Sci. 1051 (2005), 506–514.
86. Valencia, X., Stephens, G., Goldbach-Mansky, R., Wilson, M., Shevach, E.M., Lipsky, P.E., TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108:1 (2006), 253–261.
87. Huang, Z., Yang, B., Shi, Y., Cai, B., Li, Y., Feng, W., Fu, Y., Luo, L., Wang, L., Anti-TNF-alpha therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell. Immunol. 279:1 (2012), 25–29.
88. Nadkarni, S., Mauri, C., Ehrenstein, M.R., Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 204:1 (2007), 33–39.
89. Nie, H., Zheng, Y., Li, R., Guo, T.B., He, D., Fang, L., Liu, X., Xiao, L., Chen, X., Wan, B., Chin, Y.E., Zhang, J.Z., Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat. Med. 19:3 (2013), 322–328.
90. Zaragoza, B., Chen, X., Oppenheim, J.J., Baeyens, A., Gregoire, S., Chader, D., Gorochov, G., Miyara, M., Salomon, B.L., Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat. Med. 22:1 (2016), 16–17.
91. Chen, X., Wu, X., Zhou, Q., Howard, O.M., Netea, M.G., Oppenheim, J.J., TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J. Immunol. (Baltimore, Md.: 1950) 190:3 (2013), 1076–1084.
92. Chopra, M., Riedel, S.S., Biehl, M., Krieger, S., von Krosigk, V., Bauerlein, C.A., Brede, C., Jordan Garrote, A.L., Kraus, S., Schafer, V., Ritz, M., Mattenheimer, K., Degla, A., Mottok, A., Einsele, H., Wajant, H., Beilhack, A., Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 34:6 (2013), 1296–1303.
93. Grinberg-Bleyer, Y., Saadoun, D., Baeyens, A., Billiard, F., Goldstein, J.D., Gregoire, S., Martin, G.H., Elhage, R., Derian, N., Carpentier, W., Marodon, G., Klatzmann, D., Piaggio, E., Salomon, B.L., Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J. Clin. Investig. 120:12 (2010), 4558–4568.
94. McCann, F.E., Perocheau, D.P., Ruspi, G., Blazek, K., Davies, M.L., Feldmann, M., Dean, J.L., Stoop, A.A., Williams, R.O., Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. (Hoboken, N.J.) 66:10 (2014), 2728–2738.
95. Nguyen, D.X., Ehrenstein, M.R., Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J. Exp. Med. 213:7 (2016), 1241–1253.
96. Vos, A.C., Wildenberg, M.E., Arijs, I., Duijvestein, M., Verhaar, A.P., de Hertogh, G., Vermeire, S., Rutgeerts, P., van den Brink, G.R., Hommes, D.W., Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm. Bowel Dis. 18:3 (2012), 401–408.
97. Sondermann, P., Szymkowski, D.E., Harnessing Fc receptor biology in the design of therapeutic antibodies. Curr. Opin. Immunol. 40 (2016), 78–87.
98. Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J.F., Watier, H., Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19:5 (2004), 511–519.
99. Louis, E.J., Watier, H.E., Schreiber, S., Hampe, J., Taillard, F., Olson, A., Thorne, N., Zhang, H., Colombel, J.F., Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet. Genomics 16:12 (2006), 911–914.
100. Moroi, R., Endo, K., Kinouchi, Y., Shiga, H., Kakuta, Y., Kuroha, M., Kanazawa, Y., Shimodaira, Y., Horiuchi, T., Takahashi, S., Shimosegawa, T., FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 65:4 (2013), 265–271.
101. Ternant, D., Berkane, Z., Picon, L., Gouilleux-Gruart, V., Colombel, J.F., Allez, M., Louis, E., Paintaud, G., Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn's disease. Clin. Pharmacokinet. 54:5 (2015), 551–562.
102. Lee, C.H., Choi, D.K., Choi, H.J., Song, M.Y., Kim, Y.S., Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris. Protein Expr. Purif. 71:1 (2010), 42–48.
103. Mahadevan, U., Wolf, D.C., Dubinsky, M., Cortot, A., Lee, S.D., Siegel, C.A., Ullman, T., Glover, S., Valentine, J.F., Rubin, D.T., Miller, J., Abreu, M.T., Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol.: Official Clin. Practice J. Am. Gastroenterol. Assoc. 11:3 (2013), 286–292 quiz e24.